Clover Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Clover Health (Nasdaq: CLOV) will report its fourth quarter and full year 2025 financial results after market close on Thursday, February 26, 2026, and host a webcast at 5:00 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clover Health (Nasdaq: CLOV) will report its fourth quarter and full year 2025 financial results after market close on Thursday, February 26, 2026, and host a webcast at 5:00 p.m. Eastern Time.
The webcast will be available live and archived for 12 months on Clover Health investor relations, and registration is available via the provided webcast link.
Details
News Market Reaction – CLOV
On Jan 30, the first trading day after this news, CLOV closed 1.32% below the previous close.
Data tracked by StockTitan Argus for the Jan 30 session.
Key Figures
- Earnings release date
- February 26, 2026
- Q4 and full year 2025 results release after market close
- Earnings call time
- 5:00 p.m. Eastern Time
- Scheduled start of Q4 and full year 2025 webcast
- Webcast availability
- 12 months
- Archived webcast accessible on Investor Relations site
Historical Context
-
Strong MA membership growth and outlook for 2026 GAAP profitability.
-
AI-enabled platform metrics showing improved medical cost ratios and outcomes.
-
Announcement of presentation at J.P. Morgan 2026 Healthcare Conference.
-
Participation in the 2025 Citi Global Healthcare Conference.
-
Q3 results with strong revenue growth, raised guidance, but GAAP net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter.
Fourth Quarter and Full Year 2025 Conference Webcast Details:
- What: Clover Health’s Fourth Quarter and Full Year 2025 Earnings Conference Call
- When: Thursday, February 26, 2026, at 5:00 p.m. Eastern Time
- Webcast: To access the webcast, you may register at https://clover-health-q425-earnings-call.open-exchange.net/.
A live and archived webcast of the conference call will also be accessible from the Investor Relations section of Clover Health’s website at https://investors.cloverhealth.com/ for 12 months.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Investor Relations:
Ryan Schmidt
investors@cloverhealth.com
Press Inquiries:
press@cloverhealth.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.